Qualigen therapeutics secures worldwide rights to g4-selective transcription inhibitors from university college london to develop as cancer therapeutics

Preclinical therapeutic program to be initially focused on pancreatic cancer

QLGN Ratings Summary

QLGN Quant Ranking